News in brief: HFrEF PBS listing for dapagliflozin; Cardiology professor commercialises oral milrinone; AMA calls for healthcare staff to receive boosters

Dapagliflozin PBS listing recommendation for HFrEF Dapagliflozin’s (Forxiga) PBS listing could soon extend to heart failure with reduced ejection fraction (HFrEF) following the PBAC’s recent recommendation. It comes after additional information from AstraZeneca proved estimated impacts of listing dapagliflozin for HFrEF on top of type 2 diabetes were “broadly reasonable” and “an appropriate basis for ...

Already a member?

Login to keep reading.

© 2021 the limbic